Company Analysis
Sign in

CalciMedica, Inc. (CALC)

Nasdaq: CALC · Pharmaceutical Preparations · La Jolla, CA · filing with the SEC since 2011
Full chart Alerts Compare
Grade4.3
◀ Past 2.7● Present 3.3▶ Future 6.2
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

47 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to CalciMedica, Inc.’s names, not what it holds today.

Patents granted
47
47 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 3 in 2023
Applications published
82
1 of them in 2025
Names they are printed under
3
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
CALCIMEDICA, INC. its own name
US, as the owner printed on each patent
35 granted
34 published
Graybug Vision, Inc. a former name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
12 granted
23 published
CalciMedica, Inc. its own name
named as the applicant on its applications, in US
0 granted
25 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Feb 20, 202411,905,248Compounds that modulate intracellular calciumPharmaceuticalsCALCIMEDICA, INC.
Sep 12, 202311,752,148Pyrazine-containing compoundPharmaceuticalsCALCIMEDICA, INC.
Jan 31, 202311,564,890Aggregating microparticles for medical therapyPharmaceuticalsGraybug Vision, Inc.
Jan 10, 202311,548,861Drugs and compositions for the treatment of ocular disordersOrganic fine chemistryGraybug Vision, Inc.
Sep 13, 202211,439,639Pyrazine-containing compoundPharmaceuticalsCALCIMEDICA, INC.
Aug 9, 202211,407,781Equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphatesPharmaceuticalsGraybug Vision, Inc.
Apr 26, 202211,311,535Pancreatitis treatmentPharmaceuticalsCALCIMEDICA, INC.
Nov 2, 202111,160,870Extended release microparticles and suspensions thereof for medical therapyPharmaceuticalsGraybug Vision, Inc.
May 25, 202111,013,737Pyrazine-containing compoundPharmaceuticalsCALCIMEDICA, INC.
Nov 3, 202010,821,109Pyrazine-containing compoundPharmaceuticalsCALCIMEDICA, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Apr 17, 20252025/0120969METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGSPharmaceuticalsCalciMedica, Inc.
Sep 19, 20242024/0307384PYRAZINE-CONTAINING COMPOUNDPharmaceuticalsCalciMedica, Inc.
Mar 21, 20242024/0092745DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERSOrganic fine chemistryGraybug Vision, Inc.
Feb 22, 20242024/0058332CRAC CHANNEL INHIBITOR COMPOSITIONSPharmaceuticalsCalciMedica, Inc.
Feb 8, 20242024/0041783AGGREGATING MICROPARTICLES FOR MEDICAL THERAPYPharmaceuticalsGraybug Vision, Inc.
Jan 11, 20242024/0010638IMPROVED SYNTHESIS OF CRAC CHANNEL INHIBITORSOrganic fine chemistryCalciMedica, Inc.
Jul 20, 20232023/0226058METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURYPharmaceuticalsCalciMedica, Inc.
Apr 20, 20232023/0120819METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROMEPharmaceuticalsCalciMedica, Inc.
Feb 23, 20232023/0058971EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPYPharmaceuticalsGraybug Vision, Inc.
Feb 23, 20232023/0056284EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPYPharmaceuticalsGraybug Vision, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CALC · research, not advice